VERWENDUNG VON IGF-1

PCT No. PCT/SE93/00425 Sec. 371 Date Feb. 1, 1994 Sec. 102(e) Date Feb. 1, 1994 PCT Filed May 14, 1993 PCT Pub. No. WO93/23071 PCT Pub. Date Nov. 25, 1993.The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus. the medicament comprisin...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SOENKSEN, PETER, H, SAVAGE, MARTIN, O, DUNGER, DAVID, B
Format: Patent
Sprache:ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SOENKSEN, PETER, H
SAVAGE, MARTIN, O
DUNGER, DAVID, B
description PCT No. PCT/SE93/00425 Sec. 371 Date Feb. 1, 1994 Sec. 102(e) Date Feb. 1, 1994 PCT Filed May 14, 1993 PCT Pub. No. WO93/23071 PCT Pub. Date Nov. 25, 1993.The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus. the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_ATE207758TT1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ATE207758TT1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_ATE207758TT13</originalsourceid><addsrcrecordid>eNrjZBAJcw0Kd_VzCfVzVwjz91PwdHfTNeRhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfGOIa5GBubmphYhIYbGxKgBAHhyHwM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>VERWENDUNG VON IGF-1</title><source>esp@cenet</source><creator>SOENKSEN, PETER, H ; SAVAGE, MARTIN, O ; DUNGER, DAVID, B</creator><creatorcontrib>SOENKSEN, PETER, H ; SAVAGE, MARTIN, O ; DUNGER, DAVID, B</creatorcontrib><description>PCT No. PCT/SE93/00425 Sec. 371 Date Feb. 1, 1994 Sec. 102(e) Date Feb. 1, 1994 PCT Filed May 14, 1993 PCT Pub. No. WO93/23071 PCT Pub. Date Nov. 25, 1993.The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus. the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.</description><edition>7</edition><language>ger</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2001</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20011115&amp;DB=EPODOC&amp;CC=AT&amp;NR=E207758T1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20011115&amp;DB=EPODOC&amp;CC=AT&amp;NR=E207758T1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SOENKSEN, PETER, H</creatorcontrib><creatorcontrib>SAVAGE, MARTIN, O</creatorcontrib><creatorcontrib>DUNGER, DAVID, B</creatorcontrib><title>VERWENDUNG VON IGF-1</title><description>PCT No. PCT/SE93/00425 Sec. 371 Date Feb. 1, 1994 Sec. 102(e) Date Feb. 1, 1994 PCT Filed May 14, 1993 PCT Pub. No. WO93/23071 PCT Pub. Date Nov. 25, 1993.The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus. the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2001</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZBAJcw0Kd_VzCfVzVwjz91PwdHfTNeRhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfGOIa5GBubmphYhIYbGxKgBAHhyHwM</recordid><startdate>20011115</startdate><enddate>20011115</enddate><creator>SOENKSEN, PETER, H</creator><creator>SAVAGE, MARTIN, O</creator><creator>DUNGER, DAVID, B</creator><scope>EVB</scope></search><sort><creationdate>20011115</creationdate><title>VERWENDUNG VON IGF-1</title><author>SOENKSEN, PETER, H ; SAVAGE, MARTIN, O ; DUNGER, DAVID, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_ATE207758TT13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>ger</language><creationdate>2001</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>SOENKSEN, PETER, H</creatorcontrib><creatorcontrib>SAVAGE, MARTIN, O</creatorcontrib><creatorcontrib>DUNGER, DAVID, B</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SOENKSEN, PETER, H</au><au>SAVAGE, MARTIN, O</au><au>DUNGER, DAVID, B</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>VERWENDUNG VON IGF-1</title><date>2001-11-15</date><risdate>2001</risdate><abstract>PCT No. PCT/SE93/00425 Sec. 371 Date Feb. 1, 1994 Sec. 102(e) Date Feb. 1, 1994 PCT Filed May 14, 1993 PCT Pub. No. WO93/23071 PCT Pub. Date Nov. 25, 1993.The invention relates to the use of IGF-1 for the manufacture of a medicament for treatment of Type 1 diabetes mellitus. the medicament comprising a subcutaneous dose not greater than needed to achieve an IGF-1 serum level characteristic for healthy individuals i.e. a physiological replacement of serum IGF-1. This treatment would be especially valuable for the treatment of children or adolescents with Type 1 diabetes mellitus and could lead to improvements in their pubertal growth.</abstract><edition>7</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language ger
recordid cdi_epo_espacenet_ATE207758TT1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title VERWENDUNG VON IGF-1
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T11%3A29%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SOENKSEN,%20PETER,%20H&rft.date=2001-11-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EATE207758TT1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true